Evinacumab, whether administered intravenously or subcutaneously, significantly reduced low-density lipoprotein cholesterol (LDL-C), by greater than 50% at the highest dose levels, as compared to placebo, and the drug was generally well-tolerated, according to late-breaking trial results presented Sunday at the American Heart Association Scientific Sessions 2020 virtual conference.